A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5498-501. doi: 10.1016/j.bmcl.2011.06.111. Epub 2011 Jul 2.

Abstract

A novel outer mitochondrial membrane protein containing [2Fe-2S] clusters, mitoNEET was first identified through its binding to the anti-diabetic drug pioglitazone. Pioglitazone belongs to a family of drugs that are peroxisome proliferator-activated receptor (PPAR) gamma agonists, collectively known as glitazones. With the lack of pharmacological tools available to fully elucidate mitoNEET's function, we developed a binding assay to probe the glitazone binding site with the aim of developing selective and high affinity compounds. We used multiple thiazolidine-2,4-dione (TZD), 2-thioxothiazolidin-4-one (TTD), and 2-iminothiazolidin-4-one (ITD) compounds to establish several trends to enhance ligand development for the purpose of elucidating mitoNEET function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites / drug effects
  • Dose-Response Relationship, Drug
  • Ligands
  • Mitochondrial Proteins / antagonists & inhibitors*
  • Mitochondrial Proteins / metabolism
  • Molecular Structure
  • Recombinant Proteins / antagonists & inhibitors
  • Recombinant Proteins / metabolism
  • Rosiglitazone
  • Stereoisomerism
  • Structure-Activity Relationship
  • Thiazolidinediones / chemical synthesis
  • Thiazolidinediones / chemistry
  • Thiazolidinediones / pharmacology*

Substances

  • CISD1 protein, human
  • Ligands
  • Mitochondrial Proteins
  • Recombinant Proteins
  • Thiazolidinediones
  • Rosiglitazone